ACETAdicet TherapeuticsNot started yet
A Phase 1/2 Trial of ADI-212 in mCRPC
Prostate Cancer Metastatic
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 12 (planned)
- Started
- Sep 2026
- Main results expected
- Oct 2028
- Fully finished
- Oct 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
The incidence of Subjects with Dose Limiting Toxicity within each dose level
Measured over: Day 42
Proportion of treatment emergent and treatment related Adverse Events
Measured over: 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07793435 · record last updated 2026-09-10 · checked 2026-11-09 15:47 UTC